231 related articles for article (PubMed ID: 24240485)
1. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
Kim EK; Kong SJ; Chung SK
Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
3. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
4. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
5. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.
Türkcü FM; Cinar Y; Türkcü G; Sahin A; Cingü AK; Yüksel H; Sahin M; Yıldırım A; Caça I
Cutan Ocul Toxicol; 2014 Jun; 33(2):138-44. PubMed ID: 23859535
[TBL] [Abstract][Full Text] [Related]
6. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
7. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
8. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
Ahn YJ; Hwang HB; Chung SK
Korean J Ophthalmol; 2014 Apr; 28(2):177-80. PubMed ID: 24688262
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
11. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
[TBL] [Abstract][Full Text] [Related]
12. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab.
Chu HS; Chen TC; Hu FR; Chen WL
Cornea; 2013 Nov; 32(11):1446-53. PubMed ID: 24055900
[TBL] [Abstract][Full Text] [Related]
14. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
16. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.
Kim YC; Grossniklaus HE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2014 Sep; 55(11):7376-86. PubMed ID: 25212779
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
18. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
20. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
